FDA Issues Final Guidance on Bioequivalence Studies for Topical Dermatologic Corticosteroids
July 14, 2026
July 14, 2026
WASHINGTON, July 14 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration issued final guidance on July 14 outlining recommendations for bioequivalence studies for topical dermatologic corticosteroids.
The guidance, titled Topical Dermatologic Corticosteroids: In Vivo Bioequivalence, is intended for applicants submitting abbreviated new drug applications (ANDAs) for topical corticosteroids across all potency groups. It describes an in vivo pharmaco . . .
The guidance, titled Topical Dermatologic Corticosteroids: In Vivo Bioequivalence, is intended for applicants submitting abbreviated new drug applications (ANDAs) for topical corticosteroids across all potency groups. It describes an in vivo pharmaco . . .